GLP-1 Users Are Exercising Less While Losing Weight, New Study Finds

Since this outlet's June 17 coverage of GLP-1 research linking the drugs to reduced violent behavior, a separate study has surfaced raising a different kind of concern: people on these medications may be exercising less, not more, as the weight comes off.

Fox News reported the findings, citing a new study examining physical activity levels among GLP-1 receptor agonist users — the drug class that includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound). The study found that users were reducing their exercise during the weight-loss period, a pattern researchers flagged as a potential problem.

Why This Matters Beyond the Scale

Weight loss achieved primarily through caloric suppression — which is how GLP-1s work — without corresponding physical activity can result in significant muscle mass loss alongside fat loss. Muscle loss accelerates with age, raises fall risk, slows metabolism, and erodes cardiovascular health.

Medically supervised weight loss programs have long emphasized that the composition of weight lost matters as much as the number on the scale. Losing 40 pounds that is 30% lean muscle is a very different health outcome than losing 40 pounds that is almost entirely fat.

What the Study Found

The Fox News report does not name the journal or lead researchers in the excerpt available, which limits independent verification of the specific methodology. The study's precise design — whether it tracked steps, gym attendance, metabolic rate, or self-reported activity — affects how seriously to weigh the findings.

What can be said: the concern is scientifically plausible. GLP-1 drugs work partly by slowing gastric emptying and reducing appetite signals. Some researchers have speculated that similar satiety-pathway suppression could blunt motivation for voluntary physical exertion, though that mechanism has not been confirmed in humans as of June 17, 2026.

The Strongest Counter-Argument

Defenders of GLP-1 prescribing patterns have a fair point: many patients starting these drugs are obese, have joint pain, metabolic syndrome, or other conditions that physically limit exercise. Expecting a 300-pound person with knee problems to immediately begin a fitness regimen is unrealistic. For those patients, appetite suppression that produces any weight loss at all may be the prerequisite that eventually makes exercise possible rather than the thing that prevents it.

The sequencing question — whether reduced activity during early GLP-1 use leads to worse outcomes compared to never losing the weight at all — is not settled by this study.

What Doctors Have Been Saying

Endocrinologists and obesity medicine specialists have consistently recommended that GLP-1 prescriptions be paired with structured dietary guidance and physical activity coaching. The American College of Sports Medicine has emphasized resistance training specifically for GLP-1 users to preserve lean muscle mass during rapid weight loss.

The gap between that clinical recommendation and what patients are actually doing in practice — which is what this study appears to be measuring — has been a known concern in the field for the past two years as prescriptions scaled from thousands to tens of millions.

As of June 17, 2026, more than 15 million Americans are estimated to be on some form of GLP-1 medication, according to reporting from multiple health outlets over the past year. Even a modest reduction in physical activity across that population has population-scale implications for cardiovascular and musculoskeletal health.

The Open Question

The study as reported does not tell us whether reduced exercise during GLP-1 use produces measurably worse long-term health outcomes versus people who lost the same amount of weight through diet alone or other means. Comparative outcome data — specifically on body composition, bone density, and cardiovascular markers at two and five years — would tell physicians whether activity counseling needs to become a mandatory component of GLP-1 prescriptions rather than a suggested one.